Clinical Trial Update: Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA [Phase 1, Phase 2]

View source ↗

Summary

This Phase 1/Phase 2 clinical trial is evaluating the combination of canakinumab and darbepoetin alfa in patients with lower-risk myelodysplastic syndromes who …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• ARANESP (DARBEPOETIN ALFA)
• ILARIS (canakinumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING